Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 4 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

Results 1 - 20 of 29 : 1 2 Next »

Recs

0
Member Avatar SubPrime (57.51) Submitted: 7/29/2014 3:34:54 PM : Outperform Start Price: $1.83 CRIS Score: -6.12

Looking for bump from earnings.

Recs

0
Member Avatar TruffelPig (< 20) Submitted: 4/1/2014 10:02:26 PM : Outperform Start Price: $2.99 CRIS Score: -47.95

Recent news and ZZ

Recs

1
Member Avatar zzlangerhans (99.78) Submitted: 3/29/2014 8:43:26 AM : Outperform Start Price: $2.83 CRIS Score: -46.44

I've never had real money on Curis, but it would seem to me that the key to managing the trade would be low expectations. Expect weak revenues from Erivedge, at least one early stage trial termination or clinical hold, and glacially slow progress from partner Debiopharm. Try to pick up shares close to the one year low and start selling when you're up 20%. This stock is not going to be your multibagger. When the floor is caving in under the sector, avoid completely. There's nothing but 70M in cash to create a bottom here.

Recs

0
Member Avatar TerryHoodSr (60.36) Submitted: 8/6/2013 10:28:16 PM : Outperform Start Price: $3.98 CRIS Score: -75.10

spec

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $4.10 CRIS Score: +75.95

Short. Biotech. Revenues have dried up. Issuing lots of stock and raising debt. Big losses.

Recs

0
Member Avatar RBuskey106 (52.91) Submitted: 3/14/2012 10:40:32 PM : Outperform Start Price: $4.54 CRIS Score: -104.70

Skin cancer drug approved. Working closely with Roche--buyout potential

Recs

1
Member Avatar louisfool (81.55) Submitted: 10/28/2011 3:32:42 PM : Underperform Start Price: $3.72 CRIS Score: +109.15

Will underperform until approved. Look for a big pop once that happens.

Recs

0
Member Avatar Lcrazylegs84 (< 20) Submitted: 9/17/2011 6:26:12 PM : Outperform Start Price: $3.17 CRIS Score: -112.71

Its on a up hill battle..

Recs

1
Member Avatar waderjw (65.88) Submitted: 7/14/2011 10:54:21 AM : Outperform Start Price: $3.90 CRIS Score: -107.33

They're having good trial runs on their cancer drugs.

Recs

1
Member Avatar EclecticRecluse (79.57) Submitted: 5/4/2011 4:50:35 AM : Underperform Start Price: $3.72 CRIS Score: +100.90

High Price with Low Professional Opinion

Recs

0
Member Avatar thundiyi (< 20) Submitted: 2/4/2011 11:32:43 AM : Outperform Start Price: $2.94 CRIS Score: -94.01

This stock has huge potential on the upside ($40 per share), and relatively low risk on the downside ($.75). They have financial support from large succesful organizations such as genetech and they have many avenues and ways to attempt to end various forms of cancer. This is currently the best attempt we have at ending certain types of cancer.

Recs

2
Member Avatar tttchicattt (98.41) Submitted: 9/8/2010 2:21:34 AM : Outperform Start Price: $1.27 CRIS Score: -44.90

tmfbravobevo

Recs

0
Member Avatar jimmy8756309 (69.39) Submitted: 8/31/2010 2:11:00 AM : Outperform Start Price: $1.24 CRIS Score: -50.17

at 52 week low

Recs

1
Member Avatar HB2 (83.46) Submitted: 8/9/2010 11:07:58 AM : Outperform Start Price: $1.56 CRIS Score: -65.79

I currently own

Recs

0
Member Avatar runneil (< 20) Submitted: 7/13/2010 7:29:22 AM : Outperform Start Price: $1.50 CRIS Score: -67.22

tough stock to own without the market winds at your back. a double is likley as good news on hedgehog still likely but any more bad news and....poof!

Recs

0
Member Avatar franktejon (< 20) Submitted: 7/2/2010 7:05:00 PM : Outperform Start Price: $1.52 CRIS Score: -78.54

strong buy

Recs

0
Member Avatar tunnel99 (< 20) Submitted: 5/21/2010 12:58:26 PM : Outperform Start Price: $3.31 CRIS Score: -132.41

This is going to be an outstanding stock for long term investor...More institutions investors invest in this small cap company.. Next year is going to be a great year!

Recs

0
Member Avatar HIGHG33K (88.88) Submitted: 5/21/2010 3:08:19 AM : Outperform Start Price: $3.19 CRIS Score: -134.65

ASCO

Recs

0
Member Avatar popsie100 (< 20) Submitted: 2/15/2010 2:10:49 PM : Outperform Start Price: $2.52 CRIS Score: -114.93

The bright prospects Curis (CRIS) has have been ignored by the major movers on Wall Street. CRIS has 3 drugs in Phase 3 trials. In two of those trials they are partnering with Genetech, which is running the trials (and is now owned by Roche). One of these trials is a 100 person pivotal trial to show the long term effectiveness of their drug designed to cure basal cell carcinoma (BCC). This same drug had a very high overall response rate in a smaller Phase 2 BCC trial . Right now this same compound is being tested in many Phase 2 trials (to trest other cancers) sponsored by the National Cancer Institute and other prestigious health providers. I am a owner of CRIS.

Recs

0
Member Avatar crapsshooter (88.66) Submitted: 12/18/2009 2:24:56 PM : Outperform Start Price: $2.85 CRIS Score: -121.28

No real reason just like the way this company looks.

Results 1 - 20 of 29 : 1 2 Next »

Featured Broker Partners


Advertisement